Journal Scans
Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
Pertuzumab Is Active After Trastuzumab Failure in HER2+ Breast Cancer
J Baselga, KA Gelmon, S Verma, A Wardley, PF Conte, D Miles, G Bianchi, J Cortes, VA McNally, GA Ross, P Fumoleau, L Gianni
20100201
2010 Mar 1
J Clin Oncol
Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
J Clin Oncol. 2010 Mar 1;28(7):1138-1144, J Baselga, KA Gelmon, S Verma, A Wardley, PF Conte, D Miles, G Bianchi, J Cortes, VA McNally, GA Ross, P Fumoleau, L Gianni
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Despite the success of the HER2-targeted monoclonal antibody trastuzumab in improving survival in patients with advanced HER2-positive breast cancer, there is still a need for treatment options in metastatic disease when trastuzumab fails. Pertuzumab is a humanized monoclonal antibody that inhibits HER-mediated signaling by binding to a different HER2 epitope than trastuzumab. Because trastuzumab and pertuzumab have complementary mechanisms of action, pertuzumab is a good candidate for use in combination...
